KYSCO logo

Trial Details

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)

NCT06109779

RECRUITING

DESCRIPTION


A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent.

CONDITIONS


Biliary Tract Cancer

ELIGIBILITY CRITERIA


Trial Location Information

Research Site

Lexington

Kentucky

40506


Loading...